Mobile

PPAR Alpha (LY518674): a Phase 2 Dose-Response Study to Evaluate the Blood Pressure-Lowering Effect in Essential Hypertension

Update Il y a 4 ans
Reference: EUCTR2005-004966-17

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

to test the hypothesis that LY518674, administered for 6 weeks to patients with mild essential hypertension, reduces 24-hour mean ambulatory SBP, compared with placebo.

Inclusion criteria

  • mild essential hypertension

Links